English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine Clinical Trials
HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies
Aug 28, 2023 20:23 HKT
HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies
Aug 28, 2023 19:30 HKT
WholisticResearch Reveals the Best Nootropics of 2023
Aug 18, 2023 06:00 HKT
Asensus Surgical Continues to Spearhead Innovations and Growth in Surgical Robotics
Aug 17, 2023 21:00 HKT
亿胜生物公布2023年中期业绩 收入同比增长37.1% 净利润同比增长22.0%
Aug 16, 2023 19:08 HKT
億勝生物公佈2023年中期業績 收入同比增長37.1% 淨利潤同比增長22.0%
Aug 16, 2023 19:07 HKT
Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22%
Aug 16, 2023 19:06 HKT
亿胜生物宣布贝伐珠单抗眼科适应症I/II期临床研究成功完成
Jul 26, 2023 19:00 HKT
億勝生物宣布貝伐珠單抗眼科適應症I/II期臨床研究成功完成
Jul 26, 2023 18:59 HKT
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed
Jul 26, 2023 18:58 HKT
HanchorBio Announces Taiwan FDA IND Approval for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies
Jul 24, 2023 20:19 HKT
HanchorBio Announces Taiwan FDA IND Approval for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies
Jul 24, 2023 19:30 HKT
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP) Platform
Jul 20, 2023 16:00 HKT
中国三大ICL服务提供商之一艾迪康于香港联交所主板正式挂牌
Jun 30, 2023 14:27 HKT
中國三大ICL服務提供者之一艾迪康於香港聯交所主板正式掛牌
Jun 30, 2023 14:26 HKT
ADICON Holdings Limited One of the Top Three ICL Service Providers in China is Successfully Listed on Main Board of SEHK
Jun 30, 2023 14:25 HKT
医疗板块布局正当时,关注新股ICL龙头艾迪康带来的投资机遇
Jun 21, 2023 07:07 HKT
醫療板塊佈局正當時,關注新股ICL龍頭艾迪康帶來的投資機遇
Jun 21, 2023 07:06 HKT
艾迪康宣布于港交所主板上市计划 每股作价12.32港元
Jun 19, 2023 11:39 HKT
艾迪康宣佈於港交所主板上市計劃 每股作價12.32港元
Jun 19, 2023 11:38 HKT
<< Previous  Next >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: